MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with <i>KRAS</i> alterations
MEKi-based combinatorial therapies had modest disease control in patients with KRAS G12R, and minimal disease control in patients with KRAS G12D/V in the late-line setting.
Authors
- R. Kurzrock
- Mandana Kamgar (ORCID: https://orcid.org/0000-0001-9364-2712)
- Elizabeth Auckley
- B. George
- Grace W Ying
- S. Thalji
- M. Aldakkak
- Thomas McFall (ORCID: https://orcid.org/0000-0002-5284-6994)
- Stephanie Yohay
- J. Grahl
- Jacquelyn Wittmann
- Aniko Szabo
Institutions
- Froedtert Hospital (US)
- Medical College of Wisconsin (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1093/oncolo/oyag040
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00